The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Abstract
Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. This study demonstrates that the trifunctional bsAb BiLu is able to kill tumor cells very efficiently without any additional costimulation of effector cells in vitro and in vivo. Remarkably, this bsAb also induces a long-lasting protective immunity against the targeted syngeneic mouse tumors (B16 melanoma and A20 B-cell lymphoma, respectively). A strong correlation was observed between the induction of a humoral immune response with tumor-reactive antibodies and the survival of mice. This humoral response was at least in part tumor specific as shown in the A20 model by the detection of induced anti-idiotype antibodies. Both the survival of mice and antitumor titers were significantly diminished when F(ab′)2 fragments of the same bsAb were applied, demonstrating the importance of the Fc region in this process. With the use of T-cell depletion, a contribution of a cellular antitumor response could be demonstrated. These results reveal the necessity of the Fc region of the bsAb with its potent immunoglobulin subclass combination mouse immunoglobulin G2a (IgG2a) and rat IgG2b. The antigen-presenting system seems to be crucial for achieving an efficient tumor cell killing and induction of long-lasting antitumor immunity. Hereby, the recruitment and activation of accessory cells by the intact bsAb is essential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal studies, 100% of mice administered an injection of 4 μg of triomabs survived after intraperitoneal (IP) injection of a lethal dose of EpCAM + melanoma cells. 25”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [25]
In the citing paper
“All mice rechallenged on day 144 after the primary challenge were still able to reject the tumor, indicating the high efficacy and long duration of the antitumor response.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [25]
In the citing paper
“This effect was dependent on the presence of the hybrid Fc, and involved a humoral response directed against the non-transfected (EPCAM -) tumor cells.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [25]
Citations
Cites
1 retracted
Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., et al. (2000) · Nature Medicine · doi:10.1038/73193 · Cited by 637
RetractedDranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., et al. (1999) · Nature Medicine · doi:10.1038/13928 · Cited by 591
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
Gong, J., Chen, D., Kashiwaba, M., & Kufe, D. W. (1997) · Nature Medicine · doi:10.1038/nm0597-558 · Cited by 591
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.
Litvinov, S. V., Velders, M. P., Bakker, H. A. M., Fleuren, G. J., & Warnaar, S. O. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.125.2.437 · Cited by 525
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
French, R. R., Chan, H. T. C., Tutt, A. L., & Glennie, M. J. (1999) · Nature Medicine · doi:10.1038/8426 · Cited by 426
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213
Self-citationZeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204
Self-citationHeo, D. S., Park, J. G., Hata, K., Day, R., Herberman, R. B., & Whiteside, T. L. (1990) · PubMed · Cited by 192
Zeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189
Self-citationCure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
Renner, C., Jung, W. E., Şahin, U., Denfeld, R. W., Pohl, C., Trümper, L. H. P., Hartmann, F., Diehl, V., van Lier, R. A. W., & Pfreundschuh, M. G. (1994) · Science · doi:10.1126/science.8171337 · Cited by 156
FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy
Valerius, T., Stockmeyer, B., van Spriel, A. B., Graziano, R. F., van den Herik–Oudijk, I. E., Repp, R., Deo, Y. M., Lund, J., Kalden, J. R., Gramatzki, M., et al. (1997) · Blood · doi:10.1182/blood.v90.11.4485 · Cited by 130
Visual inspection with acetic acid in the early detection of cervical cancer and precursors
Sankaranarayanan, R., Shyamalakumary, B., Wesley, R., Amma, N. S., Parkin, D. M., & Nair, M. K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990105)80:1 · Cited by 114
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
Dohlsten, M., Hansson, J., Ohlsson, L., Litton, M. J., & Kalland, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9791 · Cited by 68
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma
Weiner, G. J., & Hillstrom, J. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.4035 · Cited by 67
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner, G. J., Kostelny, S. A., Hillstrom, J. R., Cole, M. S., Link, B. K., Wang, S. L., & Tso, J. Y. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.5.2385 · Cited by 64
Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIII
Weiner, L. M., Clark, J. I., Ring, D. B., & Alpaugh, R. K. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.453 · Cited by 57
Daniel, P. T., Kroidl, A., Kopp, J., Sturm, I., Moldenhauer, G., Dörken, B., & Pezzutto, A. (1998) · Blood · doi:10.1182/blood.v92.12.4750 · Cited by 56
Miescher, G. C., Schreyer, M., & MacDonald, H. R. (1989) · Immunology Letters · doi:10.1016/0165-2478(89)90122-3 · Cited by 55
Qian, J. H., Titus, J. A., Andrew, S. M., Mezzanzanica, D., Garrido, M. A., Wunderlich, J. R., & Segal, D. M. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3250 · Cited by 49
Renner, C., Jung, W. E., Şahin, U., van Lier, R. A. W., & Pfreundschuh, M. G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250734 · Cited by 44
Heijnen, I., Rijks, L. J. M., Schiel, A. E., Stockmeyer, B., van Ojik, H. H., Dechant, M., Valerius, T., Keler, T., Tutt, A. L., Glennie, M. J., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5629 · Cited by 44
Guo, Y.-J., Che, X.-Y., Shen, F., Xie, T., Ma, J., Wang, X. N., Wu, S. G., Anthony, D. D., & Wu, M. C. (1997) · Nature Medicine · doi:10.1038/nm0497-451 · Cited by 39
Jonge, J. D., Heirman, C., Veerman, M. D., Meirvenne, S. V., Moser, M., Léo, O., & Thielemans, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.3.1454 · Cited by 38
Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3
Coulie, P. G., Uyttenhove, C., Wauters, P., Manolios, N., Klausner, R. D., Samelson, L. E., & Snick, J. V. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210718 · Cited by 34
Clark, M., Gilliland, L. K., & Waldmann, H. (1988) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000318799 · Cited by 30
Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.
Mocikat, R., Selmayr, M., Thierfelder, S., & Lindhofer, H. (1997) · PubMed · Cited by 28
Self-citationBohlen, H., Manzke, O., Titzer, S., Lorenzen, J., Kube, D., Engert, A., Abken, H., Wolf, J. M., Diehl, V., & Tesch, H. (1997) · PubMed · Cited by 26
Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models
Lindhofer, H., Menzel, H., Günther, W., Hültner, L., & Thierfelder, S. (1996) · Blood · doi:10.1182/blood.v88.12.4651.bloodjournal88124651 · Cited by 26
Self-citationGoing both ways: bispecific antibodies and targeted cellular cytotoxicity
Fanger, M. W., Segal, D. M., & Wunderlich, J. R. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.11.2199282 · Cited by 23
Reinecke, K., Mysliwietz, J., & Thierfelder, S. (1994) · Transplantation · doi:10.1097/00007890-199402150-00026 · Cited by 15
Hombach, A. A., Mathas, S., Jensen, M., Tillmann, T., Menges, M., Diehl, V., Kruis, W., & Pohl, C. (1997) · PubMed · Cited by 4
Cited by
Sorted by citations
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 603
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknavičienė, B., Razbadauskas, A., Gore, M. E., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 548
Self-citationMonoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 435
Metadata
- Authors
- Ruf, P., & Lindhofer, H.
- Affiliations
- Helmholtz Munich (DE)
- ORCID
- Ruf, Peter
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-10-15
- Volume
- 98
- Issue
- 8
- Pages
- 2526-2534
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1972848082
- Cited by
- 174
- References
- 34
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 11 · 2015: 9 · 2014: 15 · 2013: 9 · 2012: 16
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- bispecific antibodies, trifunctional antibody, antitumor immunity, Fc fragment, humoral immune response, anti-idiotypic antibodies, T cell depletion, antigen-presenting cells, B16 melanoma, tumor cell killing, immunoglobulin G2a, tumor-specific antibodies
- MeSH terms
- Animals, Antibodies, Neoplasm, Antibody Formation, Antibody Specificity, Cytotoxicity, Immunologic, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Immunoglobulin G, Immunoglobulin Idiotypes, Immunoglobulin Fab Fragments, Immunoglobulin Fc Fragments, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Survival Rate, Antibodies, Bispecific, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
